Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04917835
Other study ID # 3-2019-0239
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 15, 2019
Est. completion date May 6, 2020

Study information

Verified date June 2021
Source Gangnam Severance Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the efficacy and safety of argon-and nitrogen- non-thermal, atmospheric-pressure plasma (NTAPP) for reduction of sebum excretion in healthy volunteers with oily facial skin.


Description:

Excessive secretion of sebum contributes to several skin diseases associated with sebum glands, including acne. Excessive sebum secretion can damage the skin barrier function by changing the composition of skin surface lipids, leading to the abnormal keratinocyte differentiation and hyperkeratosis in the follicular ostia. Follicular hyperkeratosis can create anaerobic environment, leading to the proliferation of Propionibacterium acnes. Recently, several energy devices targeting sebaceous glands have been developed, but there is still a need for an effective and safe therapeutic tool for hyperseborrhea. Non-thermal, atmospheric-pressure plasma (NTAPP) has various biological effects. A recent study demonstrated NTAPP-induced microscopic tissue reactions in the sebaceous glands from rat skin in vivo, suggesting that the potential effect of NTAPP on the human sebaceous gland physiology, but the relevant data are lacking. In this study, investigators aim to assess the safety and efficacy of argon- and nitrogen-NTAPP for reduction of sebum excretion in oily human facial skin.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date May 6, 2020
Est. primary completion date April 9, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 40 Years
Eligibility Inclusion Criteria: 1. Persons aged 19 to 40 years who are determined to have oily skin type. Skin types were classified based on the sebum measurements by using measured using a Sebumeter® (SM815; Courage+Khazaka Electronic GmbH, Cologne, Germany) according to the manufacturer's guidelines as follows: > 220 µg/cm2 on forehead and > 180 µg/cm2 on cheeks, oily type; 100-220 µg/cm2 on forehead and 70-180 µg/cm2 on cheeks, normal type; < 100 µg/cm2 on forehead and < 70 µg/cm2 on cheeks, dry type. 2. People with mild acne-like skin whose upper limit is Grade 1 (Few lesions; No nodules, papules/pustules less than 1, few comedones) and Grade 2(Mild; No nodules, papules/pustules less than 5, some comedones) of the Korean acne severity system 3. Persons who skin color of type I to III according to Fitzpatrick skin type 4. Persons who do not have inflammatory skin diseases on the facial skin 5. Persons who have heard the purpose and contents of a clinical trial and voluntarily signed the consent form prior to the clinical trial 6. Persons who can be monitored during a clinical trial period Exclusion Criteria: 1. Persons who do not want this study or do not write a consent form 2. Persons who have a history of hypertrophic scars, keloids, etc. 3. Persons who have been using retinoid formulations within the last 1 month due to excessive sebum secretion or acne 4. Persons who have a history of receiving treatments such as lasers or fillers on your face within the last 1 month 5. Persons who is pregnant or lactating, or have a pregnancy plan within the expected trial period 6. Other cases in which the study is considered difficult due to the judgment of the principal investigator

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PLADUO(PX1000)
Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.

Locations

Country Name City State
Korea, Republic of GangnamSeverance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Gangnam Severance Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of casual sebum level (µg/cm 2) The change in the casual sebum level is determined by measuring Sebumter® (SM815) from the German company Courage-khazaka. The measurement is performed in the three facial areas: forehead (mid-glabella), right and left cheeks (over the zygoma at the mid-pupillary line). baseline, 2 weeks, 4 weeks, and 8 weeks after treatment
Primary Change in the number of Ki67-and PPAR-gamma-positive sebaceous gland cells in facial tissue following treatment with argon- and nitrogen-NTAPP Among subjects who completed the study, 2-mm skin punch biopsy specimens were obtained from zygomatic area of two volunteered subjects before and 2 weeks after argon- and nitrogen- non-thermal, atmospheric-pressure plasma treatment. baseline and 2 weeks after treatment
See also
  Status Clinical Trial Phase
Completed NCT05138835 - BOTOX® Cosmetic and Skin Health. N/A
Completed NCT01640028 - Exploratory Study of Intra and Inter-subject Variability in Sebum Excretion Rate N/A
Completed NCT01254162 - Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers Phase 2
Completed NCT02597777 - Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin N/A